Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

VCs love few things more than a proven ex­ec­u­tive team when it comes to launch­ing a new com­pa­ny. And now a group of A-lis­ters has turned to a pair of top ex­ecs out of AveX­is to steer the lat­est gene ther­a­py play­er in­to the clin­ic.

The biotech is Waltham, MA-based Affinia and the two ex­ecs are Sean Nolan and Rick Mo­di — the for­mer CEO and CBO re­spec­tive­ly of AveX­is, the gene ther­a­py pi­o­neer that fetched $8.7 bil­lion in a sale to No­var­tis. Nolan has now tak­en the chair­man’s role at Affinia while Mo­di moves up to the CEO post at the com­pa­ny.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN